Skip to main content
. 2017 Mar 11;4(1):e000591. doi: 10.1136/openhrt-2017-000591

Figure 2.

Figure 2

Patient distribution. A total of 103 participants were randomised into the V+A and V+T groups, but the data of 97 were subject to final analysis (48 in the V+A group and 49 in the V+T group). V+A, valsartan with aliskiren; V+T, valsartan with trichlormethiazide.